Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant   [X]

Filed by a Party other than the Registrant   [   ]

Check the appropriate box:

[X]     Preliminary Proxy Statement
[   ]      Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
[   ]      Definitive Proxy Statement
[   ]      Definitive Additional Materials
[   ]      Soliciting Material Pursuant to Section 240.14a-12

NOT APPLICABLE
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):
[X]      No fee required.
[   ]      Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

[   ]      Fee paid previously with preliminary materials.

[   ]      Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

This Preliminary Proxy Statement is being filed with the SEC pursuant to Rule 14a-6 of the Securities Exchange Act of 1934. TapImmune Inc. intends to release a Definitive Proxy Statement substantially in the form hereof to its shareholders on or about December 30, 2008, although such date (as well as the other dates as set forth in this Preliminary Proxy Statement) are subject to change in the discretion of TapImmune Inc., in compliance with any and all applicable laws, rules and regulations.

On behalf of the board of directors of TapImmune Inc. (the "Company"), I cordially invite you to attend a Special Meeting of stockholders to be held at the offices of Lang Michener LLP, Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia, Canada, on Thursday, January 22, 2009 at 10:00 a.m. Pacific Time.

At the Special Meeting, you will be asked to consider and vote upon the following proposals:

1. a proposal to amend the Company's Articles of Incorporation to increase the Company's authorized shares of common stock from 80,000,000 shares of common stock to 500,000,000 shares of common stock with the same par value of $0.001 per share (the Company's number of authorized shares of preferred stock, par value $0.001 per share, shall remain unchanged at 5,000,000 shares); and
2. a proposal to adjourn the Special Meeting, if necessary or appropriate, to solicit additional Proxies.

The proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital will not be effectuated unless the proposal is approved by the holders of at least a majority of the voting power of the outstanding shares of our common stock. Your vote is important. We encourage you to read the accompanying Proxy Statement in its entirety. You may also obtain additional information about TapImmune Inc. from documents filed with the Securities and Exchange Commission.

If you sign, date and send your Proxy and do not indicate how you want to vote, your Proxy will be voted "FOR" the proposal to increase the Company's authorized share capital and "FOR" the proposal to adjourn the Special Meeting, if necessary or appropriate, to solicit additional Proxies, provided that no Proxy that is specifically marked "AGAINST" the proposal to increase the Company's authorized share capital will be voted in favor of the adjournment proposal, unless it is specifically marked "FOR" the adjournment proposal.

To Be Held On January 22, 2009

We will hold a Special Meeting of the stockholders of TapImmune Inc. (the "Company") at the offices of Lang Michener LLP, Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia, Canada, on Thursday, January 22, 2009 at 10:00 a.m. Pacific Time. The purpose of the Special Meeting will be:

Only holders of record of our common stock at the close of business on December 17, 2008, the record date for the Special Meeting, may vote at the Special Meeting. Each share of our common stock is entitled to one vote on each matter to be voted upon at the Special Meeting.

For more information about the proposed amendment to the Company's Articles of Incorporation to increase the Company's authorized share capital, please review the accompanying Proxy Statement.

This Preliminary Proxy Statement is dated December 10, 2008.

The Definitive Proxy Statement will first be mailed to stockholders
on or about December 30, 2008.

This Proxy Statement and the accompanying Proxy Card are furnished to the holders of common stock of TapImmune Inc., a Nevada corporation (the "Company"), by the Board of Directors of the Company (the "Board of Directors"), in connection with a Special Meeting of the stockholders of TapImmune Inc. (the "Company") to be held at the offices of Lang Michener LLP, Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia, Canada, on Thursday, January 22, 2009 at 10:00 a.m. Pacific Time. The purpose of the Special Meeting will be:

The Board of Directors has approved, and recommends the shareholders of the Company approve, the proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital. If this proposal is approved by the shareholders of the Company, it will be effected by the filing of a Certificate of Amendment to the Articles of Incorporation of the Company with the Secretary of State of Nevada.

This Proxy Statement, together with the Notice of Special Meeting of Stockholders and the accompanying Proxy Card, is to be first mailed to Company shareholders on or about December 30, 2008.

The following questions and answers address briefly some questions you may have regarding the Special Meeting and the proposed amendment to the Company's Articles of Incorporation to increase the Company's authorized share capital. These questions and answers may not address all questions that may be important to you as a stockholder of TapImmune Inc. Please refer to the more detailed information contained elsewhere in this Proxy Statement. In this Proxy Statement, the terms "Company," "we," "our," "ours," and "us " refer to TapImmune Inc.

A: The Company's board of directors has determined that it is in the Company's best interests to amend the Company's Articles of Incorporation to increase the Company's authorized share capital. The Company needs the approval of at least a majority of the voting power of the outstanding shares of our common stock in order to amend its Articles of Incorporation. Our board of directors is providing this Proxy Statement to give you information for use in determining how to vote on the proposals submitted to the stockholders at the Special Meeting of our stockholders. You should read this Proxy Statement carefully. The enclosed Proxy Card allows you, as our stockholder, to vote your shares without attending the Special Meeting.

A: The Special Meeting of stockholders will take place at the offices of Lang Michener LLP, Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia, Canada, on Thursday, January 22, 2009 at 10:00 a.m. Pacific Time.

A: You will vote on a proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital and a proposal to adjourn the Special Meeting for the purpose of soliciting additional Proxies, if necessary or appropriate.

A: All stockholders as of the close of business on December 17, 2008, the record date for the Special Meeting, are entitled to receive notice of and to attend and vote or submit a Proxy to vote at the Special Meeting. If you want to attend the Special Meeting and your shares are held in an account at a brokerage firm, bank or other nominee, you will need to bring a copy of your voting instruction card or brokerage statement reflecting your stock ownership as of the record date.

A: The proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital must be approved by the holders of at least a majority of our outstanding shares of common stock. The proposal to adjourn the Special Meeting to solicit additional proxies must be approved by the holders of a majority of the voting power represented at the Special Meeting, provided that a quorum, which, pursuant to our Bylaws, consists of a majority of our outstanding shares entitled to vote at any meeting, is present in person on by proxy.

A: Our board of directors recommends that you vote "FOR" the proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital and "FOR" the proposal to adjourn the Special Meeting for the purpose of soliciting additional Proxies, if necessary or appropriate.

A: The purpose of the proposed increase in the Company's authorized share capital is to make available additional shares of common stock for issuance for general corporate purposes, including financing activities, without the requirement of further action by the shareholders of the Company. The Board of Directors believes that increasing the authorized number of shares of the common stock of the Company will provide the Company with greater flexibility and allow the issuance of additional shares of common stock in most cases without the expense or delay of seeking further approval from the shareholders. The Company is at all times investigating additional sources of financing which the Board of Directors believes will be in the Company's best interests and in the best interests of the shareholders of the Company.

A: For each share of our common stock that you own on December 17, 2008, the record date for the Special Meeting, you are entitled to cast one vote on each matter voted upon at the Special Meeting.

A: Yes, your vote is important. Since we need the approval of a majority all of our outstanding shares to approve the amendment of the Company's Articles of Incorporation to increase the Company's authorized share capital, your vote is important.

A: Before you vote, you should read this Proxy Statement in its entirety and carefully consider how the proposed amendment to the Company's Articles of Incorporation to increase the Company's authorized share capital may affect you. Then, if you were a holder of record at the close of business on December 17, 2008, you may vote by submitting a Proxy for the Special Meeting. You can submit your Proxy by completing, signing, dating and returning the enclosed Proxy Card in the accompanying preaddressed envelope. You may also attend the Special Meeting and vote your shares in person whether or not you sign and return your Proxy Card.

A: If you abstain from voting, fail to cast your vote in person or by Proxy or fail to give voting instructions to your broker, bank or nominee, it will have the same effect as a vote against the proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital and the proposal to adjourn the Special Meeting for the purpose of soliciting additional Proxies.

If you sign, date and send your Proxy Card and do not indicate how you want to vote, your Proxy will be voted "FOR" the proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital and "FOR" the proposal to adjourn the Special Meeting for the purpose of soliciting additional Proxies, if necessary, provided that no Proxy that is specifically marked "AGAINST" the proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital will be voted in favor of the adjournment proposal, unless it is specifically marked "FOR" the adjournment proposal.

A: If you hold your shares in "street name," which means your shares are held of record by a broker, bank or nominee, you must provide the record holder of your shares with instructions on how to vote your shares in accordance with the voting directions provided by your broker, bank or nominee. If you do not provide your broker, bank or nominee with instructions on how to vote your shares, it will not be permitted to vote your shares. This will have the same effect as voting against the proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital. Please consult your broker, bank or nominee to determine how to submit your voting instructions to the record holder of your shares.

A: Yes, you may revoke and change your vote at any time before your Proxy Card is voted at the Special Meeting. You can do this in one of three ways:

If you have instructed a broker, bank or other nominee to vote your shares, you must follow the directions received from your broker, bank or other nominee to change those instructions.

A: You may receive more than one set of voting materials, including multiple copies of this Proxy Statement and multiple Proxy Cards. For example, if you hold your shares in more than one brokerage account, you may receive a set of voting materials for each brokerage account in which you hold shares. If you are a holder of record and your shares are registered in more than one name, you will receive more than one Proxy Card. Please complete, sign, date and return each Proxy Card that you receive.

A: We file Annual Reports on Form 10-KSB, which include our audited financial statements, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and our Proxy Statements with the Securities and Exchange Commission. You may read and copy these Reports, Proxy Statements and other information at the Securities and Exchange Commission's Public Reference Section at 100 F Street, N.E., Washington, DC 20549. You may obtain information on the operation of the Public Reference Room by calling the Securities and Exchange Commission at 1-800-SEC-0330. The Securities and Exchange Commission also maintains an Internet website, located at www.sec.gov, that contains these Reports, Proxy Statements and other information regarding TapImmune Inc. and other registrants that file electronically with the Securities and Exchange Commission.

A: If you have any questions about the proposed amendment to the Company's Articles of Incorporation to increase the Company's authorized share capital or how to submit your Proxy, or if you need additional copies of this Proxy Statement or the enclosed Proxy Card, please call the Company at the telephone number listed below. If you would like additional copies, without charge, of this Proxy Statement you should contact:

The proposed amendment to the Company's Articles of Incorporation to increase the Company's authorized share capital requires approval of the Company's shareholders under Nevada corporate law. Pursuant to the Company's Articles of Incorporation and Bylaws and Nevada corporate law, the approval of at least a majority of the voting power of the outstanding shares of our common stock is required in order to approve the amendment to the Company's Articles of Incorporation to effectuate the increase in authorized share capital. The Company will hold a Special Meeting of its stockholders at the offices of Lang Michener LLP, Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia, Canada, on Thursday, January 22, 2009 at 10:00 a.m. Pacific Time for the purpose of:

If you were a holder of record of the Company's shares at the close of business on December 17, 2008, you may vote on these matters by submitting a Proxy for the Special Meeting. You can submit your Proxy by completing, signing, dating and returning the enclosed Proxy Card in the accompanying preaddressed envelope. You may also attend the Special Meeting and vote your shares in person whether or not you sign and return your Proxy Card. The deadline for the delivery to the Company of written Proxies is the date and time of the Special Meeting, which is Thursday, January 22, 2009 at 10:00 a.m. Pacific Time.

If you sign, date and send your Proxy Card and do not indicate how you want to vote, your Proxy will be voted "FOR" the proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital and "FOR" the proposal to adjourn the Special Meeting for the purpose of soliciting additional Proxies, if necessary, provided that no Proxy that is specifically marked "AGAINST" the proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital will be voted in favor of the adjournment proposal, unless it is specifically marked "FOR" the adjournment proposal. The deadline for the delivery to the Company of written Proxies is the date and time of the Special Meeting, which is Thursday, January 22, 2009 at 10:00 a.m. Pacific Time.

The Board of Directors has fixed the close of business on December 17, 2008, as the record date (the "Record Date") for the determination of shareholders entitled to vote on the matters described herein. Only shareholders of the Company as of the Record Date are entitled to tender and submit to the Company written Proxies. As of December 17, 2008, there were _____________ shares of the Company's common stock issued and outstanding. The common stock constitutes the sole outstanding class of voting securities of the Company. Each share of common stock entitles the holder thereof to one vote on all matters submitted to shareholders.

Solicitation of Proxies by the Board will initially be made by mail, but may also be made in person or by mail, telephone, telecopy, telegram, facsimile or other means of communication by Directors, Officers and regular employees of the Company for no additional or special compensation. In addition, brokerage houses, banks, nominees, trustees, custodians and other fiduciaries may be requested by the Company to forward Proxy solicitation materials for shares of common stock held of record by them to the beneficial owners of such shares, and such fiduciaries will, upon request, be reimbursed by the Company for their reasonable out of pocket expenses incurred in connection therewith. The cost of solicitation of written Proxies to approve and consent to the corporate actions described herein will be borne by the Company.

The corporate action authorizing the amendment of our Articles of Incorporation to increase our authorized share capital will be adopted when properly completed, unrevoked Proxies are signed by shareholders of record of Company representing at least a majority of the voting power of the outstanding shares of common stock and submitted to the Company; provided, however, that all Proxies will expire, unless delivered and present to the Company, by the date and time of the Special Meeting, which is Thursday, January 22, 2009 at 10:00 a.m. Pacific Time.

The Company plans to present the results of a successful solicitation with respect to the corporate actions proposed herein as soon as possible. Shareholders are requested to tender and submit their completed Proxy Card to the Company at the following address:

Abstentions and "broker non-votes" (shares held of record by brokers or nominees which are not voted on a particular matter because the broker or nominee has not received voting instructions from the beneficial owner of such shares and does not have discretionary voting power with respect to that matter) will be treated as votes against the corporate actions described herein.

If a Proxy Card is properly signed and returned to the Company on or before the date and time of the Special Meeting, which is Thursday, January 22, 2009 at 10:00 a.m. Pacific Time, unless properly revoked, the shares represented by that Proxy Card will be voted in accordance with the instructions specified thereon. If a Proxy Card is properly signed and returned to the Company without voting instructions, it will be voted "FOR" the proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital and "FOR" the proposal to adjourn the Special Meeting for the purpose of soliciting additional Proxies, if necessary, provided that no Proxy that is specifically marked "AGAINST" the proposal to amend the Company's Articles of Incorporation to increase the Company's authorized share capital will be voted in favor of the adjournment proposal, unless it is specifically marked "FOR" the adjournment proposal.

You may revoke your Proxy Card or change your vote at any time before your Proxy Card is voted at the Special Meeting. You can do this in one of three ways:

If you have instructed a broker, bank or other nominee to vote your shares, you must follow the directions received from your broker, bank or other nominee to change those instructions.

The Board of Directors is seeking shareholder approval to amend the Company's Articles of Incorporation to increase the Company's authorized shares of common stock from 80,000,000 shares of common stock to 500,000,000 shares of common stock with the same par value of $0.001 per share (the Company's number of authorized shares of preferred stock, par value $0.001 per share, shall remain unchanged at 5,000,000 shares). purpose of this proposed increase in authorized share capital is to make available additional shares of common stock for issuance for general corporate purposes, including financing activities, without the requirement of further action by the shareholders of the Company. The Board of Directors has considered potential uses of the additional authorized shares of common stock, which may include the seeking of additional equity financing through public or private offerings, establishing additional employee or director equity compensation plans or arrangements or for other ge neral corporate purposes. Increasing the authorized number of shares of the common stock of the Company will provide the Company with greater flexibility and allow the issuance of additional shares of common stock in most cases without the expense or delay of seeking further approval from the shareholders. The Company is at all times investigating additional sources of financing which the Board of Directors believes will be in the Company's best interests and in the best interests of the shareholders of the Company.

The shares of common stock do not carry any pre-emptive rights. The adoption of the amendment to the Company's Articles of Incorporation to increase the Company's authorized share capital will not of itself cause any changes in the Company's capital accounts.

The increase in authorized share capital will not have any immediate effect on the rights of existing shareholders. However, the Board of Directors will have the authority to issue authorized shares of common stock without requiring future approval from the shareholders of such issuances, except as may be required by applicable law or exchange regulations. To the extent that additional authorized shares of common stock are issued in the future, they will decrease the existing shareholders' percentage equity ownership interests and, depending upon the price at which such shares of common stock are issued, could be dilutive to the existing shareholders. Any such issuance of additional shares of common stock could have the effect of diluting the earnings per share and book value per share of outstanding shares of common stock of the Company.

One of the effects of the proposed increase in authorized share capital, if adopted, however, may be to enable the Board of Directors to render it more difficult to or discourage an attempt to obtain control of the Company by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of present management. The Board of Directors would, unless prohibited by applicable law, have additional shares of common stock available to effect transactions (including private placements) in which the number of the Company's outstanding shares would be increased and would thereby dilute the interest of any party attempting to gain control of the Company. Such action, however, could discourage an acquisition of the Company which the shareholders of the Company might view as desirable.

The Company has no current plans, proposals or arrangements to issue any of the additional shares that will become authorized share capital of the Company pursuant to the proposed increase in authorized share capital described herein.

Under Nevada law the Company's shareholders are not entitled to appraisal rights with respect to the increase in authorized share capital.

The following table sets forth information as of December 17, 2008, concerning: (i) each person who is known by the Company to be the beneficial owner of more than 5% of the Company's outstanding common stock as well as by each of our current directors and executive officers and (ii) the beneficial ownership of the Company's outstanding common stock by the Company's directors and officers as a group.